MX2007013171A - Metodo para alterar la especificidad de union de las proteinas mediante reacciones de oxido-reduccion. - Google Patents

Metodo para alterar la especificidad de union de las proteinas mediante reacciones de oxido-reduccion.

Info

Publication number
MX2007013171A
MX2007013171A MX2007013171A MX2007013171A MX2007013171A MX 2007013171 A MX2007013171 A MX 2007013171A MX 2007013171 A MX2007013171 A MX 2007013171A MX 2007013171 A MX2007013171 A MX 2007013171A MX 2007013171 A MX2007013171 A MX 2007013171A
Authority
MX
Mexico
Prior art keywords
antibody
protein
mom
further characterized
binding
Prior art date
Application number
MX2007013171A
Other languages
English (en)
Spanish (es)
Inventor
John A Mcintyre
Original Assignee
Redox Reactive Reagents L L C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redox Reactive Reagents L L C filed Critical Redox Reactive Reagents L L C
Publication of MX2007013171A publication Critical patent/MX2007013171A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2007013171A 2005-04-19 2006-04-06 Metodo para alterar la especificidad de union de las proteinas mediante reacciones de oxido-reduccion. MX2007013171A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/108,826 US9557325B2 (en) 2003-06-09 2005-04-19 Method of altering the binding specificity of proteins by oxidation-reduction reactions
PCT/US2006/012802 WO2006113139A2 (en) 2005-04-19 2006-04-06 Method of altering the binding specificity of proteins by oxidation-reduction reactions

Publications (1)

Publication Number Publication Date
MX2007013171A true MX2007013171A (es) 2008-01-18

Family

ID=37115646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013171A MX2007013171A (es) 2005-04-19 2006-04-06 Metodo para alterar la especificidad de union de las proteinas mediante reacciones de oxido-reduccion.

Country Status (9)

Country Link
US (1) US9557325B2 (https=)
EP (1) EP1871171A4 (https=)
JP (1) JP2008536920A (https=)
CN (1) CN101262774A (https=)
AU (1) AU2006236928B2 (https=)
BR (1) BRPI0608373A2 (https=)
CA (1) CA2602635C (https=)
MX (1) MX2007013171A (https=)
WO (1) WO2006113139A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
AU2004248155B2 (en) * 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
US8372387B2 (en) * 2007-04-05 2013-02-12 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US7989596B2 (en) * 2007-09-19 2011-08-02 Redox-Reactive Reagents Llc Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
EP2326952B1 (en) * 2008-09-04 2015-07-29 Redox-Reactive Reagents, Llc Method for diagnosing, monitoring, and/or staging alzheimer's disease
US20120107841A1 (en) * 2010-07-19 2012-05-03 Mcintyre John A Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease
JP2012046470A (ja) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Ｇａｐｄｈの酵素活性阻害剤
CN102818896B (zh) * 2011-06-09 2014-12-17 北京华大蛋白质研发中心有限公司 一种基于特异抗体的硝基化修饰位点的检测方法及特异识别scot硝基化位点的抗体
EP2836845B1 (en) 2012-04-13 2018-05-09 DiabetOmics, Inc. Maternal biomarkers for gestational diabetes
WO2016081413A1 (en) * 2014-11-17 2016-05-26 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
ES2748117T3 (es) * 2015-04-22 2020-03-13 Euroimmun Medizinische Labordiagnostika Ag Diagnóstico de una nueva enfermedad autoinmune
CN113490539A (zh) * 2019-05-29 2021-10-08 松下知识产权经营株式会社 检测方法和检测装置
KR102576252B1 (ko) * 2021-04-07 2023-09-11 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물
CN118526489B (zh) * 2024-05-24 2025-04-01 南通大学 一种脱镁叶绿酸乙酯的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703001A (en) 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4950612A (en) 1987-12-16 1990-08-21 Microgenics Corporation Peroxy acid pretreatment in vitamin B12 assay
US5061790A (en) 1989-07-10 1991-10-29 Molecular Diagnostics, Inc. Oxidative denaturation of protein analytes
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US6660267B1 (en) 1992-12-21 2003-12-09 Promega Corporation Prevention and treatment of sepsis
AU703814B2 (en) 1995-12-04 1999-04-01 Wyeth Antioxidant
US5939394A (en) 1996-01-18 1999-08-17 Fleming & Company Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
FR2794461B1 (fr) 1999-06-07 2004-01-23 Lab Francais Du Fractionnement Procede de preparation de nouvelles fractions d'ig humaines possedant une activite immunomodulatrice
FR2822238B1 (fr) 2001-03-16 2003-08-29 Gemac Methode et trousse pour le suivi des maladies neurodegeneratives
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
AU2004248155B2 (en) 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions

Also Published As

Publication number Publication date
CA2602635A1 (en) 2006-10-26
JP2008536920A (ja) 2008-09-11
CN101262774A (zh) 2008-09-10
AU2006236928A1 (en) 2006-10-26
AU2006236928B2 (en) 2011-06-23
US9557325B2 (en) 2017-01-31
EP1871171A4 (en) 2015-08-19
BRPI0608373A2 (pt) 2010-11-16
WO2006113139A3 (en) 2007-08-23
EP1871171A2 (en) 2008-01-02
CA2602635C (en) 2014-12-23
US20050260681A1 (en) 2005-11-24
WO2006113139A2 (en) 2006-10-26

Similar Documents

Publication Publication Date Title
US10072068B2 (en) Method for altering the binding specificity of plasma proteins by oxidation
MX2007013171A (es) Metodo para alterar la especificidad de union de las proteinas mediante reacciones de oxido-reduccion.
McIntyre et al. Autoantibodies unmasked by redox reactions
McIntyre The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation–reduction reactions
McIntyre et al. Redox-reactive autoantibodies: detection and physiological relevance
US7989596B2 (en) Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions
EP0345750A2 (en) Polyfunctional protease
MXPA05013402A (en) Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
Lin et al. Monoclonal IgM Antiphosphatidylserine Antibody Reacts Against Cytoskeleton‐Like Structures in Cultured Human Umbilical Cord Endothelial Cells
McIntyre et al. Autoantibody potential of cancer therapeutic monoclonal antibodies
JPH08503770A (ja) 抗ｈｐａ抗体の検出
Bloemen et al. Inverted erythrocyte membranes demonstrate β2GPI-antiphospholipid antibody interactions and membrane crosslinking
Hagen et al. A New Serum Factor in Normal Rabbits: IX. Association with Group B Immunoglobulin Allotypic Specificities
CK et al. APPEARANCE OF CYTOLYTIC ANTIBODIES IN SHEEP LYMPH FOLLOWINC IMMUNISATION WITH TUMOUR CELLS
Schlesinger et al. Treatment of mouse thymus cells with phosphatidylinositol-specific phospholipase C preferentially abrogates their reactivity with autoantibodies to the Thy-1 antigen
Roter β2-glycoprotein I-specific T cells: antigen specificity and role in the induction of anti-phospholipid syndrome

Legal Events

Date Code Title Description
FG Grant or registration